The goals of the Tissue Bank Core are to aid SPORE investigators: 1) to identify tumor biologic and molecular genetic correlates of diagnosis, prognosis, response, progression, and survival in the context of the SPORE related investigations;2) to maintain a searchable database of clinical and laboratory data for use by SPORE investigators;and 3) to provide a resource of banked specimens for future studies. Core Laboratory functions are designed to increase the power of the individual projects to detect biologic differences among patients entering the SPORE studies, to identify molecular correlates of response versus resistance, and to be flexible enough to address individual investigator needs. In the previous funding period, the tissue core received, processed, stored, archived and distributed clinically-annotated cellular (bone marrow and PB cells), molecular (DNA and RNA), and serum samples to investigators participating in this SPORE. Samples from the SPORE have been collected, tested, and archived separately from other Core resources, such as the DF/HCC and Program Project reference laboratories;however, these resources are being shared between this core resource, thereby increasing the pool of samples available for correlative science by the SPORE investigators. Importantly, in this renewal application we are now collaborating with the Intergroupe Francophone du Myeloma (IFM) in sharing archived and future samples. IFM has over 10,000 clinically annotated samples, some with long follow ups of up to 8-10 years. During last 3 years we have shared samples between our groups and generated number of joint publications. Due to the increased needs of our growing SPORE and collaborative tissue bank, we have utilized standard operating procedures for bone marrow processing, myeloma cell purification, and cryopreservation across sites here at Dana Farber and in IFM. This Core provides an independent, current, and quickly searchable database of clinical and laboratory results and archived biospecimens. Data forms completed at the time of collection of the samples are entered into a common clinical, laboratory, and archival database. Follow up data is obtained and entered as required. All data are then stored in a common database accessible by the Statistics Center. All patients have measurement of key biological variables requested by SF'ORE investigators. Unused specimen including sorted cells, DNA, RNA, and cytospin slides are stored for future use on all patients. Subsequent use of banked samples beyond that specified in this SPORE proposal will be provided only with agreement from the SPORE Director and the SPORE Principal Investigators, after approval from the SPORE Tissue Use Committee.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-0)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dana-Farber Cancer Institute
United States
Zip Code
Ye, Shuai; Lawlor, Matthew A; Rivera-Reyes, Adrian et al. (2018) YAP1-Mediated Suppression of USP31 Enhances NF?B Activity to Promote Sarcomagenesis. Cancer Res 78:2705-2720
Hunter, Zachary R; Xu, Lian; Tsakmaklis, Nickolas et al. (2018) Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia. Blood Adv 2:2937-2946
Szalat, R; Samur, M K; Fulciniti, M et al. (2018) Nucleotide excision repair is a potential therapeutic target in multiple myeloma. Leukemia 32:111-119
Bolli, Niccolò; Maura, Francesco; Minvielle, Stephane et al. (2018) Genomic patterns of progression in smoldering multiple myeloma. Nat Commun 9:3363
Gullà, A; Hideshima, T; Bianchi, G et al. (2018) Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma. Leukemia 32:996-1002
Mazzotti, Céline; Buisson, Laure; Maheo, Sabrina et al. (2018) Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow. Blood Adv 2:2811-2813
Samur, Mehmet Kemal; Minvielle, Stephane; Gulla, Annamaria et al. (2018) Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma. Leukemia 32:2626-2635
Xu, Yan; Deng, Shuhui; Mao, Xuehan et al. (2018) Tolerance, Kinetics, and Depth of Response for Subcutaneous Versus Intravenous Administration of Bortezomib Combination in Chinese Patients With Newly Diagnosed Multiple Myeloma. Clin Lymphoma Myeloma Leuk 18:422-430
Michallet, M; Chapuis-Cellier, C; Dejoie, T et al. (2018) Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients. Leukemia 32:376-382
Ray, A; Das, D S; Song, Y et al. (2018) Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma. Leukemia 32:843-846

Showing the most recent 10 out of 407 publications